Atlas Trials

STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE

Clinical trial NCT02328391 · UNKNOWN

Trial details

NCT number
NCT02328391
Sponsor
Grupo Gallego de Cancer de Pulmon
Status
UNKNOWN
Study type
OBSERVATIONAL
Carcinoma, Squamous Cell
Start date
2013-09-01
Primary completion
2015-03-01
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.